Table 1 Patients’ demographics

Age (years), mean ± SD (n = 163)

64.16 ± 6.54

BMI (kg/m²), median (IQR) (n = 153)

27.14 (24.22–29.26)

Prostate size (g), median (IQR) (n = 155)

35.6 (27.00–45.80)

PSA (ng/dl), median (IQR) (n = 158)

6.20 (4.91–8.95)

Clinical T Stage (n = 157)

cT1a

01 (0.6)

cT1c

65 (41.4)

cT2a

38 (24.2)

cT2b

20 (12.7)

cT2c

30 (19.1)

cT3

03 (1.9)

Gleason score biopsy (n = 159)

≤6

49 (30.8)

7

90 (56.6)

≥8

20 (12.6)

D’Amico risk stratification (n = 157)

Low risk

35 (22.3)

Intermediate risk

81 (51.6)

High risk

41 (26.1)

Pathologic stage (n = 163)

pT2

118 (72.3)

≥ pT3

45 (27.7)

Specimen Gleason Score (n = 163)

≤6

46 (28.2)

7

99 (60.7)

≥8

18 (11.0)